Publications by authors named "Nelly Robillard"

Claim this Profile
P
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Rémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, Lucile Baseggio, Lydia Campos, Nelly Robillard

Leukemia· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma.
Camille Debord, Jessie Bourcier, François Subiger, François Leclair, Cyrille Touzeau, Nelly Robillard

Ann Hematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.
Françoise Solly, Fanny Angelot-Delettre, Michel Ticchioni, Franck Geneviève, Hubert Rambaud, Nelly Robillard

Cytometry A· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
Pierre Peterlin, Joelle Gaschet, Thierry Guillaume, Alice Garnier, Marion Eveillard, Nelly Robillard

Cytokine· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3 ligand plasma levels in acute myeloid leukemia.
Pierre Peterlin, Joelle Gaschet, Thierry Guillaume, Alice Garnier, Marion Eveillard, Nelly Robillard

Haematologica· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Aurore Perrot, Valerie Lauwers-Cances, Jill Corre, Nelly Robillard, Cyrille Hulin

Blood· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms.
Camille Debord, Nelly Robillard, Olivier Theisen, Thomas Gastinne, Pascal Godmer

Hematol Oncol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new mutation of ANO6 in two familial cases of Scott syndrome.
Pierre Boisseau, Marie C Bene, Thomas Besnard, Sinthuja Pachchek, Mathilde Giraud, Nelly Robillard

Br J Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping.
Robin Boutault, Julian Le Glaunec, Camille Debord, Nelly Robillard, Laurent Nicolet

Br J Haematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia.
Marion Eveillard, Nelly Robillard, Isabelle Arnoux, Richard Garand, Fanny Rialland

Hematol Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.
Patrice Chevallier, Sylvain Chantepie, Francoise Huguet, Emmanuel Raffoux, Xavier Thomas, Nelly Robillard

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD180 expression in B-cell lymphomas: A multicenter GEIL study.
Caroline Mayeur-Rousse, Julien Guy, Laurent Miguet, Sabrina Bouyer, Franck Geneviève, Nelly Robillard

Cytometry B Clin Cytom· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome.
Maxime Halliez, Marc Fouassier, Nelly Robillard, Catherine Ternisien, Marianne Sigaud

Br J Haematol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Patrice Chevallier, Francoise Huguet, Emmanuel Raffoux, Anne Etienne, Thibaut Leguay, Nelly Robillard

Haematologica· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Patrice Chevallier, Thomas Eugene, Nelly Robillard, Françoise Isnard, Franck Nicolini

Lancet Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Chantal Fossat, Mikael Roussel, Isabelle Arnoux, Vahid Asnafi, Chantal Brouzes, Nelly Robillard

Cytometry B Clin Cytom· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, Cyrille Hulin, Xavier Leleu

J Clin Oncol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunophenotype of normal and myelomatous plasma-cell subsets.
Nelly Robillard, Soraya Wuillème, Philippe Moreau, Marie C Béné

Front Immunol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
Patrice Chevallier, Caroline Bodet-Milin, Nelly Robillard, Thomas Eugene, Audrey Menard

Eur J Haematol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of various blood and graft sources: a prospective series.
Patrice Chevallier, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty

Transfusion· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: a prospective series.
Patrice Chevallier, Nelly Robillard, Marina Illiaquer, Julie Esbelin, Mohamad Mohty

J Clin Virol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: a pilot series.
Patrice Chevallier, Arnaud Pigneux, Nelly Robillard, Sameh Ayari, Thierry Guillaume

Leuk Res· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study.
Patrice Chevallier, Nelly Robillard, Aude Charbonnier, Emmanuel Raffoux, Sebastien Maury

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.
Marc Fouassier, François Girodon, Cédric Cleyrat, Nelly Robillard, Richard Garand

Thromb Haemost· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Patrice Chevallier, Nelly Robillard, Sameh Ayari, Thierry Guillaume, Jacques Delaunay

Br J Haematol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis